Wall Street brokerages expect OraSure Technologies, Inc. (NASDAQ:OSUR) to announce earnings of ($0.06) per share for the current quarter, according to Zacks. Two analysts have made estimates for OraSure Technologies’ earnings. OraSure Technologies reported earnings of $0.21 per share during the same quarter last year, which suggests a negative year-over-year growth rate of 128.6%. The firm is expected to report its next earnings report on Wednesday, May 2nd.
On average, analysts expect that OraSure Technologies will report full-year earnings of $0.29 per share for the current financial year, with EPS estimates ranging from $0.24 to $0.35. For the next financial year, analysts expect that the company will post earnings of $0.51 per share, with EPS estimates ranging from $0.49 to $0.52. Zacks’ EPS calculations are an average based on a survey of sell-side research firms that cover OraSure Technologies.
OraSure Technologies (NASDAQ:OSUR) last posted its earnings results on Wednesday, February 7th. The medical instruments supplier reported $0.12 EPS for the quarter, topping analysts’ consensus estimates of $0.11 by $0.01. OraSure Technologies had a net margin of 18.52% and a return on equity of 13.09%. The business had revenue of $52.00 million for the quarter, compared to analysts’ expectations of $50.20 million. During the same period in the previous year, the company posted $0.13 earnings per share. The business’s revenue for the quarter was up 46.5% compared to the same quarter last year.
A number of research analysts have recently commented on the stock. BidaskClub cut shares of OraSure Technologies from a “strong-buy” rating to a “buy” rating in a research report on Thursday, February 15th. Zacks Investment Research lowered shares of OraSure Technologies from a “buy” rating to a “hold” rating in a research note on Tuesday, February 13th. Canaccord Genuity restated a “buy” rating and issued a $24.00 price target on shares of OraSure Technologies in a research note on Friday, February 2nd. ValuEngine lowered shares of OraSure Technologies from a “buy” rating to a “hold” rating in a research note on Thursday, November 2nd. Finally, Jefferies Group lowered shares of OraSure Technologies from a “buy” rating to a “hold” rating in a research note on Thursday, November 2nd. Three equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $22.25.
Large investors have recently modified their holdings of the stock. Oppenheimer Asset Management Inc. bought a new stake in shares of OraSure Technologies in the third quarter worth $186,000. ARP Americas LLC bought a new stake in shares of OraSure Technologies in the third quarter worth $221,000. Noesis Capital Mangement Corp bought a new stake in shares of OraSure Technologies in the third quarter worth $225,000. Shikiar Asset Management Inc. bought a new stake in shares of OraSure Technologies in the fourth quarter worth $207,000. Finally, Piedmont Investment Advisors LLC bought a new stake in OraSure Technologies during the second quarter valued at $216,000. Institutional investors and hedge funds own 89.91% of the company’s stock.
OraSure Technologies (NASDAQ OSUR) traded up $0.27 during midday trading on Thursday, hitting $18.28. 751,000 shares of the stock were exchanged, compared to its average volume of 726,381. OraSure Technologies has a twelve month low of $10.75 and a twelve month high of $23.01. The firm has a market capitalization of $1,090.00, a PE ratio of 35.29, a P/E/G ratio of 5.10 and a beta of 1.42.
ILLEGAL ACTIVITY WARNING: “Zacks: Analysts Anticipate OraSure Technologies, Inc. (OSUR) to Post -$0.06 Earnings Per Share” was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this story on another website, it was illegally copied and reposted in violation of international trademark and copyright laws. The correct version of this story can be viewed at https://www.dispatchtribunal.com/2018/02/20/zacks-analysts-anticipate-orasure-technologies-inc-osur-to-post-0-06-earnings-per-share.html.
OraSure Technologies Company Profile
OraSure Technologies, Inc (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types.
Get a free copy of the Zacks research report on OraSure Technologies (OSUR)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for OraSure Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies and related companies with MarketBeat.com's FREE daily email newsletter.